Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets

HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the geographic scope of its existing marketing and distribution agreement (the “Agreement”) for Bentrio™ with Wellesta Holding Pte Ltd (“Wellesta”) has been expanded. In addition to India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam, Wellesta will now also promote and sell Bentrio™ in the Philippines and Morocco upon registration of the product with the regulatory agencies in those two countries.

“The Philippines and Morocco, with populations of approximately 110 million and 37 million, respectively, represent two attractive new markets for Bentrio,” said Thomas Meyer, Altamira Therapeutics’ founder, Chairman and CEO. “Wellesta has proven to be a strong commercialization partner for us, and we look forward to continuing to work with its well experienced team.”

Having already obtained marketing clearances for Bentrio™ in Malaysia and Singapore, Wellesta is now making preparations and procedures for registration in the other six countries covered by the Agreement.

About Bentrio™

Bentrio™ (AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio™ forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio™ was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio™ was effective in slowing the growth of the viral titer when treatment started only 24 or 30 hours after infection. In allergy, a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours.

About Wellesta Holdings

Wellesta is a fast-growing health care company headquartered in Singapore with a direct market presence in Southeast Asia, India & North Africa. The company was founded in 2019 by two executives with more than 70 years of cumulated experience in leading multinational companies (MNCs) in health care, and the company has since grown to more than 540 employees. With strong and MNC proven leadership teams both at headquarters and in each country, Wellesta is marketing and distributing a broad range of pharmaceuticals, nutraceuticals, OTC products and medical devices from multinational companies as well as own brands. Additional information can be found on the company’s website www.wellesta.com.

About Altamira Therapeutics

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”

Forward-looking Statements

This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics’ strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of AM-301, Altamira Therapeutics’ need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics’ product candidates, the clinical utility of Altamira Therapeutics’ product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics’ intellectual property position and Altamira Therapeutics’ financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics’ capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Altamira Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2020, and in Altamira Therapeutics’ other filings with the SEC, which are available free of charge on the Securities Exchange Commission’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Investor contact:
Stephen Kilmer
(647) 872-4849
sjk@altamiratherapeutics.com

SOURCE: Altamira Therapeutics Ltd.

View source version on accesswire.com:
https://www.accesswire.com/687996/Altamira-Therapeutics-and-Wellesta-Expand-Bentrio-Marketing-and-Distribution-Agreement-to-Include-Two-Additional-Markets